Because PIK75 is not clinically available and we aimed to identify an effective combination therapy from our studies to develop a clinical trial in patients with advanced ACC, we tested a new clinical-trial-ready PI3K inhibitor, BGT226, which inhibits PI3K protein by binding to the α subunit at p110 (like PIK75) and the mTOR protein26. Here, PIK3CG is linked to adrenal cortex carcinoma.